Publication Guidelines

When publishing using data from the TriNetX network or TriNetX as a method, the following guidelines must be adhered to:

Ensuring TriNetX HIPAA Compliance and ISO 27001 Certification for Robust Protection of Healthcare Data Privacy and Security

TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2013 standard and maintains an Information Security Management System (ISMS) to ensure the protection of the healthcare data it has access to and to meet the requirements of the HIPAA Security Rule.

Any data displayed on the TriNetX Platform in aggregate form, or any patient-level data provided in a data set generated by the TriNetX Platform, only contains de-identified data as per the de-identification standard defined in Section §164.514(a) of the HIPAA Privacy Rule. The process of de-identifying data is attested to through a formal determination by a qualified expert as defined in Section §164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert was refreshed in December 2020. Please find more information about our Expert Determination here.

The TriNetX network contains data provided by participating healthcare organizations (HCOs), each of which represents and warrants that it has all necessary rights, consents, approvals, and authority to provide the data to TriNetX under a Business Associate Agreement (BAA), so long as their name remains anonymous as a data source and their data are utilized for research purposes. The data shared through the TriNetX Platform are attenuated to ensure that they do not include sufficient information to facilitate the determination of which HCO contributed which specific information about a patient.

Network to be used

The TriNetX data networks for scientific use and publications include Dataworks, Diamond, TriNetX Research, COVID-19 Rapid Response, and COVID-19 Research Network. In reasonable exceptional cases (e.g., if the topic of the project is related to clinical trials or validation of the network for use in clinical trials), other regional networks can be used. The specific network(s) used in the analysis should be disclosed in the methods section of the publication as a data source.

Use of the appropriate network

Contracts with TriNetX member HCOs do not always allow the use of their data for publications. Therefore, during review of the manuscript and discussion with the author, clarification should be sought on whether the appropriate network was used for the scientific project to be published. 

Information not to disclose

 

HCO names or HCO-specific data

Unless the publication is initiated and authored by an HCO, no HCO-specific data should be shown in any publication, not even in an anonymized way (e.g., “site 1, site 2, site 3, etc.”). All results must be shown as aggregated statistics only. HCOs may only disclose site-specific data from their own institution.

 

Platform Screenshots

Screenshots of the platform are confidential and shall not be used in any publication without express consent from TriNetX. If permission is granted, TriNetX shall provide the appropriate language relating to said screenshot(s). Graphs and associated data downloaded from the platform using the platform’s export tools can be used in publications without express consent from the TriNetX Legal Department.

Citing TriNetX

TriNetX, LLC should be mentioned in the methods section. A suggested adequate general description would read:

“The data used in this study was collected on [INSERT DATE OF ANALYSIS OR DATE OF DATA DOWNLOAD] from the TriNetX [INSERT NETWORK NAME] Network, which provided access to electronic medical records (diagnoses, procedures, medications, laboratory values, genomic information) from approximately [##] million patients from [##] healthcare organizations.”

For publication ethical considerations. A suggested adequate general description would read:

“This retrospective study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in Section §164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section §164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.”

Please note that although TriNetX recommends the above-mentioned language for publication, it may be revised as applicable.

Logo Usage

To establish and maintain the consistent and professional representation of the TriNetX logo within healthcare research partners’ publications that utilize TriNetX for its real-world data and real-world evidence generation, these guidelines ensure that the TriNetX brand, logo, and messaging align with our mission to advance healthcare research and promote data-driven insights with high-quality reproductions and displays.

 

TriNetX Logo Variations

  1. Primary Logo:
    The primary logo should be the preferred choice for all appearances of the TriNetX logo in healthcare research publications, scientific posters, and other research collateral. It consists of the TriNetX aperture icon and the horizontal TriNetX wordmark. It should be used whenever possible to maintain brand consistency. Please use the EPS vector version of all TriNetX logos to ensure the highest reproduction quality and the best visual results. Download the primary logo >>
  2. Secondary Logo:
    In cases where space or design constraints do not allow for the use of the primary logo, a secondary logo in a vertical or self-contained layout may be used. However, the primary logo should always be the first choice when possible. Download the secondary logo >>

 

TriNetX Logo Usage Guidelines

  1. Size and Placement:
    • Ensure the TriNetX logo is clearly visible and not obstructed, distorted, or pixelated.
    • Do not reduce the primary logo to a size where it becomes illegible. Use a size that retains readability and clarity.
    • Maintain a minimum clear space around the logo to avoid overcrowding. The clear space should be at least equal to the height of the “X” in the primary logo.
  2. Color and Design:
    • The TriNetX logo should always be reproduced in either all-black or all-white.
    • Do not alter colors or add design elements to the TriNetX logo.
  3. Background:
    • The TriNetX logo should always be placed on a clean, uncluttered background that provides sufficient contrast for readability.
    • Do not place the TriNetX logo on busy or distracting backgrounds.
  4. Prohibited Usage:
    • Do not distort, alter, or modify the TriNetX logo in any way.
    • Do not use outdated or unauthorized TriNetX logo versions.
    • Do not use the TriNetX logo in a way that implies endorsement or affiliation with external organizations without proper authorization.

    TriNetX Logo Request and Approval

    Any use of the TriNetX logo must be requested and approved by the TriNetX marketing department. Please email marketing@trinetx.com for logo requests and approvals.  Failure to obtain approval violates the contractual agreement between TriNetX and your institute.

    TriNetX Logo Download

    High-resolution versions of the TriNetX logo can be downloaded below:

    Primary Logo

    Download Horizontal TriNetX Logo (black):  [EPS]  |  [PNG]

    Download Horizontal TriNetX Logo (white):  [EPS]  |  [PNG]

     

    Secondary Logos

    Download Vertical TriNetX Logo (black):  [EPS]  |  [PNG]

    Download Vertical TriNetX Logo (white):  [EPS]  |  [PNG]

     

    Download Self-Contained TriNetX Logo (black):  [EPS]  |  [PNG]

    Download Self-Contained TriNetX Logo (white):  [EPS]  |  [PNG]

    Inquiries

    Please direct any additional publishing-related questions with TriNetX to your institution’s account manager or healthcare partnership manager.